-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Solid Tumor Drug Details: BOLD-100 (IT-139, NKP-1339) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Metastatic Pancreatic Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Metastatic Colorectal Cancer Drug Details: BOLD-100 (IT-139, NKP-1339)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Gastroesophageal (GE) Junction Carcinomas Drug Details: BOLD-100 (IT-139, NKP-1339) is under development for...
-
Product Insights
NewGastrointestinal Tumor – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal (GI) tumors refer to abnormal growths or neoplasms that develop in various parts of the digestive system, which includes the esophagus, stomach, intestines (small and large), liver, gallbladder, and pancreas. These tumors can be benign (non-cancerous) or malignant (cancerous). The Gastrointestinal Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with...
-
Product Insights
NewEsophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2024
Empower your strategies with our Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal squamous cell carcinoma (ESCC) is a type of cancer that arises from the squamous cells lining the esophagus, the muscular tube connecting the throat to the stomach. Commonly associated with tobacco and alcohol use, as well as dietary factors, ESCC is prevalent in certain geographic regions. Symptoms often manifest late and include difficulty swallowing, weight loss, and chest...
-
Product Insights
NewGastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024
Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Tivozanib Hydrochloride (Fotivda) is a quinoline...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986340 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986340 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986340 in Ovarian Cancer Drug Details: BMS-986340 is under development for the...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...